Fierce Drug Dev Forum 2019 has ended
Back To Schedule
Monday, October 28 • 3:15pm - 4:00pm
Case Study: Key Considerations When Evaluating AI Capabilities and Non-Molecule Driven Targets for Acquisition

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

  • Hear about a strategic investment Paragon Biosciences made in an AI platform that will allow their new portfolio company to further develop the first FDA-cleared computer-aided diagnosis system in radiology for the evaluation of breast cancer
  • Understand why AI-enabled life sciences can be a key focus area for innovation and how to approach the valuation of these emerging technologies
  • Consider the risk/reward factors associated with the acquisition and implementation of the AI platform and how that impacts the commercial forecast

avatar for James Robinson

James Robinson

President and Chief Operating Officer, PARAGON BIOSCIENCES

Monday October 28, 2019 3:15pm - 4:00pm PDT